» Articles » PMID: 31200342

Use of Direct Oral Anticoagulants Prevents Increase in Pulmonary Vascular Resistance and Incidence of Clinical Worsening in Patients with Chronic Thromboembolic Pulmonary Hypertension

Overview
Journal Thromb Res
Date 2019 Jun 15
PMID 31200342
Citations 5
Authors
Affiliations
Soon will be listed here.
Citing Articles

The use of non-vitamin K antagonist oral anticoagulants in chronic thromboembolic pulmonary hypertension: an updated meta-analysis.

Wu D, Liang H, Kaisaier W, Li J, Sun G, Dong Y J Thromb Thrombolysis. 2024; 57(7):1256-1267.

PMID: 39080118 DOI: 10.1007/s11239-024-03021-x.


Direct Oral Anticoagulants in Chronic Thromboembolic Pulmonary Hypertension: First Meta-Analysis of Prospective Studies.

Zhang T, Guo L, Liang S, Liu H Clin Appl Thromb Hemost. 2024; 30:10760296241257931.

PMID: 38778745 PMC: 11113019. DOI: 10.1177/10760296241257931.


A Multicenter, Single-Blind, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial.

Hosokawa K, Watanabe H, Taniguchi Y, Ikeda N, Inami T, Yasuda S Circulation. 2023; 149(5):406-409.

PMID: 37956127 PMC: 10814998. DOI: 10.1161/CIRCULATIONAHA.123.067528.


Efficacy and safety of edoxaban in patients with chronic thromboembolic pulmonary hypertension: protocol for a multicentre, randomised, warfarin-controlled, parallel group trial - KABUKI trial.

Hosokawa K, Abe K, Kishimoto J, Kobayakawa Y, Todaka K, Tamura Y BMJ Open. 2023; 12(7):e061225.

PMID: 37070473 PMC: 9301811. DOI: 10.1136/bmjopen-2022-061225.


Association Between Anticoagulation Outcomes and Venous Thromboembolism History in Chronic Thromboembolic Pulmonary Hypertension.

Zhu Y, Zhou Y, Wei Y, Xu X, Yan X, Liu C Front Cardiovasc Med. 2021; 8:628284.

PMID: 34095244 PMC: 8175786. DOI: 10.3389/fcvm.2021.628284.